Although the United States secured a deal with Pfizer Inc. on Wednesday. for an additional 100 million doses of its COVID-19 vaccine, cases of allergic reactions have reportedly sparked discussions between vaccine manufacturers and the National Institutes of Health (NIH) to run a clinical clinic. trials in highly allergic populations. According to a CNN report, U.S. President Donald Trump’s COVID-19 vaccine emperor said the frequency of allergic reactions to Pfizer’s vaccine was higher than expected.
“That frequency, as it was yesterday (December 22), is superior to the one we would expect from other vaccines,” said Dr. Moncef Slaoui, Chief Scientific Adviser for Operation Warp Speed, American media network.
British regulators have already issued advice on the issue, urging people with a history of “significant” allergic reactions not to take the Pfizer-BioNTech vaccine. The Medicines and Health Products Regulatory Agency (MHRA) has issued precautionary measures to the National Health Service (NHS) after two members of the health staff experienced allergic reactions. Dr June Raine, executive director of the MHRA, testified to a parliamentary committee where she acknowledged that cases of allergic reactions were not represented in extensive clinical trials.
“We know from very extensive clinical trials that this was not a feature. But if we need to strengthen our advice, now that we have this experience with vulnerable populations – groups have been selected as a priority – we get that advice immediately on the ground, “said Dr. Raine.
The United States began an immunization campaign against coronavirus disease after the Food and Drug Administration (FDA) approved emergency approval for Pfizer-BioNTech and then Modern. Under the new agreement for additional doses of Pfizer’s COVID-19 vaccine, the U.S. drugmaker and its German partner BioNTech will deliver at least 70 million doses by June 30, while the remaining doses will be delivered by July 31 at the latest.